Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention.

Autor:	Chandramohan D; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Zongo I; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Sagara I; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Cairns M; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Yerbanga RS; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Diarra M; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Nikièma F; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Tapily A; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Sompougdou F; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Issiaka D; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Zoungrana C; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Sanogo K; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Haro A; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Kaya M; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Sienou AA; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Traore S; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Mahamar A; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Thera I; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Diarra K; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Dolo A; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Kuepfer I; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Snell P; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Milligan P; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Ockenhouse C; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Ofori-Anyinam O; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Tinto H; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Djimde A; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Ouédraogo JB; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Dicko A; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.)., Greenwood B; From the London School of Hygiene and Tropical Medicine, London (D.C., M.C., I.K., P.S., P.M., B.G.); Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (I.Z., R.-S.Y., F.N., F.S., C.Z., A.H., A.-A.S., H.T., J.-B.O.); the Malaria Research and Training Center, University of Sciences, Technologies, and Techniques of Bamako, Bamako, Mali (I.S., M.D., A.T., D.I., K.S., M.K., S.T., A.M., I.T., K.D., A. Dolo, A. Djimde, A. Dicko); PATH, Seattle (C.O.); and GlaxoSmithKline Vaccines, Rixensart, Belgium (O.O.-A.).
Jazyk:	angličtina
Zdroj:	The New England journal of medicine [N Engl J Med] 2021 Sep 09; Vol. 385 (11), pp. 1005-1017. Date of Electronic Publication: 2021 Aug 25.
DOI:	10.1056/NEJMoa2026330
Abstrakt:	Background: Malaria control remains a challenge in many parts of the Sahel and sub-Sahel regions of Africa. Methods: We conducted an individually randomized, controlled trial to assess whether seasonal vaccination with RTS,S/AS01 E was noninferior to chemoprevention in preventing uncomplicated malaria and whether the two interventions combined were superior to either one alone in preventing uncomplicated malaria and severe malaria-related outcomes. Results: We randomly assigned 6861 children 5 to 17 months of age to receive sulfadoxine-pyrimethamine and amodiaquine (2287 children [chemoprevention-alone group]), RTS,S/AS01 E (2288 children [vaccine-alone group]), or chemoprevention and RTS,S/AS01 E (2286 children [combination group]). Of these, 1965, 1988, and 1967 children in the three groups, respectively, received the first dose of the assigned intervention and were followed for 3 years. Febrile seizure developed in 5 children the day after receipt of the vaccine, but the children recovered and had no sequelae. There were 305 events of uncomplicated clinical malaria per 1000 person-years at risk in the chemoprevention-alone group, 278 events per 1000 person-years in the vaccine-alone group, and 113 events per 1000 person-years in the combination group. The hazard ratio for the protective efficacy of RTS,S/AS01 E as compared with chemoprevention was 0.92 (95% confidence interval [CI], 0.84 to 1.01), which excluded the prespecified noninferiority margin of 1.20. The protective efficacy of the combination as compared with chemoprevention alone was 62.8% (95% CI, 58.4 to 66.8) against clinical malaria, 70.5% (95% CI, 41.9 to 85.0) against hospital admission with severe malaria according to the World Health Organization definition, and 72.9% (95% CI, 2.9 to 92.4) against death from malaria. The protective efficacy of the combination as compared with the vaccine alone against these outcomes was 59.6% (95% CI, 54.7 to 64.0), 70.6% (95% CI, 42.3 to 85.0), and 75.3% (95% CI, 12.5 to 93.0), respectively. Conclusions: Administration of RTS,S/AS01 E was noninferior to chemoprevention in preventing uncomplicated malaria. The combination of these interventions resulted in a substantially lower incidence of uncomplicated malaria, severe malaria, and death from malaria than either intervention alone. (Funded by the Joint Global Health Trials and PATH; ClinicalTrials.gov number, NCT03143218.). (Copyright © 2021 Massachusetts Medical Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu